Paul Lorigan

26PUBLICATIONS
159CO-AUTHORS
Gene and molecular therapyMolecular targetsPredictive and prognostic markersCross-sectional analysisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Aug 12, 2026
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

|Jul 18, 2026
Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis.

|Jul 02, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

|Jun 29, 2026
A Method for Estimating Resource Use and Costs when Empirical Data Are Unavailable: Expert Elicitation Study Using the Example of Melanoma.

|Feb 18, 2026
Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?

Rachel Woodford, Paul Lorigan, Deemesh Oudit

|Jan 19, 2026
Patterns of systemic treatment for melanoma: An insight on trends and costs between 2019-2023 from the English systemic anti-cancer therapy national database.

Tommaso Bosetti, Oliver John Kennedy, Rebecca Lee

Pageof 5

Frequent Collaborators

8 joint publications

Georgina V Long

8 joint publications

Dirk Schadendorf

7 joint publications

Paolo A Ascierto

6 joint publications

Caroline Robert